Provided by Tiger Trade Technology Pte. Ltd.

Insmed

162.53
-2.3800-1.44%
Volume:219.97K
Turnover:36.13M
Market Cap:35.03B
PE:-25.32
High:167.00
Open:163.60
Low:162.43
Close:164.91
52wk High:212.75
52wk Low:60.40
Shares:215.55M
Float Shares:193.00M
Volume Ratio:0.64
T/O Rate:0.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4200
EPS(LYR):-6.4200
ROE:-249.28%
ROA:-28.99%
PB:47.41
PE(LYR):-25.32

Loading ...

Pre-Bell | Wall St Futures Dip; Novo Nordisk Sinks 15%; Eli Lilly Gains 3%; Domino’s Pizza Jumps 5%; Arcellx Soars 78%

Tiger Newspress
·
3 hours ago

H.C. Wainwright Remains a Buy on Insmed (INSM)

TIPRANKS
·
3 hours ago

Insmed Gets UK Marketing Authorization for Non-Cystic Fibrosis Bronchiectasis Treatment

MT Newswires Live
·
3 hours ago

BRIEF-MHRA Says Licensed Brensocatib as First Drug for Non-Cystic Fibrosis Bronchiectasis in Patients Aged 12+

Reuters
·
5 hours ago

Mhra: Brensocatib Licensed as First Medicine Specifically Designed to Treat Non-Cystic Fibrosis Bronchiectasis in Patients 12 Years and Older

THOMSON REUTERS
·
5 hours ago

Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and 10x Genomics (TXG)

TIPRANKS
·
Yesterday

Insmed Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Feb 21

Insmed Q4 Reinforces Confidence in Brinsupri Growth, RBC Says

MT Newswires Live
·
Feb 20

Insmed May Top Revenue Target for Bronchiectasis Drug Brinsupri, Morgan Stanley Says

MT Newswires Live
·
Feb 20

RBC Capital Reaffirms Their Buy Rating on Insmed (INSM)

TIPRANKS
·
Feb 20

Pre-Bell | U.S. Futures Muted; Opendoor Surges 19%; AppLovin Jumps 5%; Alphabet Gains 1%; Grail Sinks 49%

Tiger Newspress
·
Feb 20

Bank of America Securities Reaffirms Their Buy Rating on Insmed (INSM)

TIPRANKS
·
Feb 20

Morgan Stanley Lifts Price Target on Insmed to $166 From $162, Keeps Equalweight Rating

MT Newswires Live
·
Feb 20

Insmed’s Brinsupri Launch Recasts Growth Outlook

TIPRANKS
·
Feb 20

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EST on 2026-02-19

Reuters
·
Feb 20

BUZZ-Insmed rises as quarterly revenue beats estimates

Reuters
·
Feb 20

Analysts Offer Insights on Healthcare Companies: Talkspace (TALK) and Insmed (INSM)

TIPRANKS
·
Feb 20

Insmed price target lowered to $205 from $212 at Stifel

TIPRANKS
·
Feb 20

Stock Track | Insmed Soars 5.38% Intraday on Strong Q4 Revenue Beat and Optimistic 2026 Guidance

Stock Track
·
Feb 20

BRIEF-Insmed Reports Fourth-Quarter And Full-Year 2025 Financial Results And Provides Business Update

Reuters
·
Feb 19